Every 10-K that InMed Pharmaceuticals Inc. (INM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow INM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INM filings page.
InMed Pharmaceuticals Inc. (INM) reported a sharp deterioration in its financial position for the year ended June 30, 2026, while winding down its only revenue-generating business. Total assets fell to $3.0 million from $15.6 million, and shareholders’ equity declined to $1.1 million from $13.4 million.
The company recorded a net loss of $12.6 million, including a $1.2 million loss from discontinued BayMedica operations, and recognized $1.46 million of intangible asset impairments plus $189,225 of equipment impairment. Cash and cash equivalents were $2.2 million, and the auditor and management both state that these conditions raise substantial doubt about InMed’s ability to continue as a going concern.
On March 4, 2026, the board approved the wind-down and exit of BayMedica’s commercial operations; as of June 30, 2026 this was substantially completed, eliminating the company’s commercial revenue stream. Remaining activities focus on preclinical development of INM-901 for Alzheimer’s disease, INM-089 for dry AMD, and INM-755 cream, but InMed does not currently intend to devote significant resources to these programs without obtaining additional financing.
InMed Pharmaceuticals (INM) filed Amendment No. 1 to its Annual Report to amend and restate Part III—Items 10–14. The update replaces director and executive biographies, compensation, beneficial ownership, related-party transactions, director independence, and auditor fee disclosures, and removes the prior reference to incorporation by reference from a proxy. Other disclosures remain unchanged.
The company reports 2,384,186 common shares outstanding as of September 17, 2025 and an aggregate market value of non‑affiliates of $3,316,582 as of December 31, 2024. FY2025 audit fees were $212,000 (total fees $229,000) with CBIZ CPAs P.C. following its acquisition of Marcum LLP’s attest business on November 1, 2024. The Board’s committees (Audit, Compensation, Governance/Nomination) are composed of independent directors; the company maintains insider trading, anti‑hedging, and clawback policies. FY2025 CEO total compensation was $396,973. A beneficial ownership table as of October 22, 2025 lists Sabby Volatility Warrant Master Fund at 280,138 shares (9.99%), subject to stated beneficial ownership limits.
InMed Pharmaceuticals Inc. (INM) 10-K highlights key operational progress, financing and risks. The company reported continued operating losses with a net loss widening to $8.69 million for the latest year and an accumulated deficit of about $117.2 million. Management states cash resources are sufficient into the fourth quarter of calendar 2026, but concluded there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Commercial operations at BayMedica are producing some revenues tied to bulk rare cannabinoids, and the company received gross proceeds of approximately $5.0 million from a private placement and $6.2 million from share issuances under a SEPA during the year.
On the R&D side, INM-901 (Alzheimer’s candidate) showed preclinical anti-inflammatory and behavioral benefits across multiple preclinical studies and was presented at AAIC 2025. INM-755 advanced through Phase 1 and a Phase 2 EB study (19 of 20 enrolled) with reported safety and some efficacy signals. The company holds multiple patent families across product and manufacturing processes and continues CMC, GLP and scale-up activities. Major risks disclosed include clinical, regulatory, intellectual property, manufacturing, controlled-substance regulation, Nasdaq listing compliance and cybersecurity.